Publications - NanoMedSyn

Publications

Therapeutic antibody engineering for efficient targeted degradation of membrane proteins in lysosomes. Biomed Pharmacother. 2024;175:116707.

Cation-independent mannose 6-phosphate receptor: From roles and functions to targeted therapies. J Control Release 2024;365:759-772.

Engineered therapeutic antibodies with mannose 6-phosphate analogues as a tool to degrade extracellular proteins. Front. Immunol. 2024.

Mannose 6-phosphate receptor-targeting antibodies preserve Fc receptor-mediated recycling. J Control Release 2023;358:465-475.

The mannose 6-phosphate receptor targeted with porphyrin-based periodic mesoporous organosilica nanoparticles for rhabdomyosarcoma theranosticsBiomater Sci 2020;8:3678-3684.

Mannose 6-phosphonate labelling: A key for processing the therapeutic enzyme in Pompe disease. J Cell Mol Med 2019;23:6499-6503.

Topological requirements for CI-M6PR-mediated cell uptake. Bioconjugate Chem. 2019; 30:2533-2538.

Efficient therapy for refractory Pompe disease by mannose 6-phosphate analogue grafting on acid alpha-glucosidase. J Control Release 2018,269:15-23.

Design of potent mannose 6-phosphate analogues for the functionalization of lysosomal enzymes to improve the treatment of Pompe disease. Angew Chem Int Ed Engl 2016,55:14774-14777.

Why anticancer nanomedicine needs sugars? Curr Med Chem 2015 ;22(26):3014-24.

Identification of MRC2 and CD209 receptors as targets for photodynamic therapy of retinoblastoma using mesoporous silica nanoparticles. RSC Adv 2015, 5, 75167-72.

Mannose-6-phosphate receptor: a target for theranostics of prostate cancer. Angew Chem Int Ed Engl. 2015 ;54(20):5952-6.

Targeting multiplicity: the key for anti-cancer nanoparticles. Curr Med Chem. 2013, 20(15):1946-55.